Medscape is available in 5 Language Editions – Choose your Edition here.


Hyperpituitarism Workup

  • Author: Alicia Diaz-Thomas, MD, MPH; Chief Editor: Stephen Kemp, MD, PhD  more...
Updated: May 28, 2014

Laboratory Studies


See the list below:

  • Serum PRL: A single PRL measurement may be sufficient to diagnose a prolactinoma if the value is greater that 200 ng/mL. Because PRL is secreted in a pulsatile fashion, a mildly increased concentration may be difficult to interpret. In this situation, casual morning samples obtained on 3 separate days should be examined before a prolactinoma is diagnosed. The serum PRL level is roughly proportional to the mass of the tumor. Small tumors can cause elevations of serum PRL lower than those values commonly observed with hyperprolactinemia from other causes.
  • Thyrotropin-releasing hormone (TRH) stimulation test: In healthy patients, intravenous TRH results in a brisk rise in serum PRL in 15-30 minutes, with peak values at least twice the baseline value. In contrast, patients with PRL-secreting tumors usually show little or no PRL increment in response to TRH, rarely exceeding a 100% rise. Patients with elevated serum PRL from other causes usually show a more normal response, with a rise in PRL of at least 100% following administration of TRH.

Adrenocorticotropic Hormone–releasing Adenoma

See the list below:

  • Urinary steroid excretion: Urinary free cortisol (UFC) excretion is a direct measurement of cortisol not bound to plasma protein and is the most reliable and useful test for assessing cortisol secretion rate. Several 24-hour UFC measurements should be obtained. UFC values should be corrected for the child's body surface area. Daily UFC excretion in excess of 70 µg (over 24 consecutive hours) in the unstressed child is highly suggestive of hypercortisolism.
  • Plasma cortisol: Normal plasma cortisol values are highest from 6-8 am, declining during the day to less than 50-80% of morning values from 8 pm to midnight. Loss of this diurnal variation of plasma cortisol is typical of Cushing disease. Cortisol should be sampled at 30-minute intervals from 6-8 am and from 8 pm to midnight.
  • Dexamethasone suppression testing: A useful screening test for hypercortisolism is the inability of dexamethasone (0.3-0.5 mg/m2, maximum dose 1 mg) administered at 11 pm to suppress the subsequent 8-am plasma cortisol concentration to less than 5 µg /dL. The suppression of 24-hour UFC excretion by more than 50% with high-dose dexamethasone (120 µg /kg/d divided qid), but not by low-dose dexamethasone (30 µg /kg/d divided qid), suggests a primary hypothalamic-pituitary disorder. Lack of suppression to high-dose dexamethasone suggests an adrenal tumor or the ectopic secretion of ACTH.
  • Plasma ACTH: Elevated or high-normal values of plasma ACTH concentration in the presence of hypercortisolism suggest that the primary pathology is due to excess ACTH secretion of pituitary or nonpituitary origin. Consistently suppressed plasma ACTH concentrations suggest that the primary disorder lies in the adrenal glands.
  • Corticotropin-releasing hormone (CRH) stimulation testing: The ACTH and cortisol responses to CRH generally are flat in the ectopic ACTH syndrome and in hypercortisolism secondary to an adrenal tumor, whereas both remain intact in Cushing disease.
  • Inferior petrosal sinus sampling
    • Sampling for ACTH venous gradients during petrosal sinus catheterization in the areas of pituitary venous drainage can offer preoperative diagnosis of a corticotropinoma and lateralization of an ACTH-secreting microadenoma to the right or left hemisphere of the pituitary gland. A gradient in ACTH levels before and/or after CRH from either side of 2 or greater can localize a microadenoma in the pituitary in over 95% of the patients and can provide lateralization information in as many as 75% of cases. Thus, even very small tumors that are not visualized by MRI can be identified and excised surgically. Of note, this procedure should be performed only in large centers with extensive experience.
    • Because no healthy patient would undergo such an invasive procedure, the referring physician must advise families that appropriate reference ranges are not available. Thus, interpretation of these data are not straightforward. Indeed, these data often obscure the management and substantially inconvenience patients and their families with an interstate trip to an elite medical center.

Growth Hormone–releasing Adenoma

See the list below:

  • Serum insulin-like growth factor-I (IGF-I): Measurement of serum IGF-I concentration is a sensitive screening test for acromegaly. Serum total (and free) IGF-I levels closely correlate to 24-hour mean integrated GH secretion. An elevated IGF-I level in a patient with appropriate clinical suspicion almost always indicates GH excess. Potential confusion may arise when evaluating healthy adolescents because significantly higher IGF-I levels occur during puberty than those during adulthood. For accurate control comparison, the IGF-I level must be compared with that of control subjects who are matched for age, gender, and Tanner stage. Note that a single measurement of GH is inadequate, because GH is secreted in a pulsatile manner during deep sleep (at night). Therefore, the use of a random GH measurement can lead to both false-positive and false-negative results and provides practically no clinically relevant data.
  • Serum insulinlike growth factor-binding protein-3 (IGFBP-3): IGFBP-3 levels may also be useful in the diagnosis of GH excess. In patients with confirmed somatotroph adenomas, increased IGFBP-3 level has been reported as a sensitive marker of GH hypersecretion and may be elevated even when circulating IGF-I levels are within the reference range.
  • Inability to suppress serum GH levels during an oral glucose tolerance test (OGTT): The single best laboratory criterion for diagnosing GH excess is failure to suppress serum GH levels to less than 5 ng/dL within 3 hours after a 1.75-g/kg oral glucose challenge (maximum dose is 75 g). This test essentially indicates the loss of negative feedback by IGF-I on GH secretion. Glucose induces insulin secretion, which suppresses hepatic IGFBP-1 release, thereby increasing circulating free IGF-I, which suppresses pituitary GH secretion. These test findings can be misleading in patients who have diabetes.

Imaging Studies

If laboratory findings suggest pituitary hormone excess, the presence of a pituitary adenoma should be confirmed using MRI. The T1-weighted spin-echo MRI of the pituitary before and after administration of gadolinium (Gd) is the imaging modality of choice for detecting pituitary adenomas.[2]

Coronal and sagittal images should be obtained at 3-mm intervals before and after contrast, focusing on the pituitary region.

Adenomas are slow to take up Gd compared with the surrounding normal pituitary tissue and therefore appear as hypoenhancing lesions.

In some cases, a pituitary mass is not identified. Be aware that a pituitary microadenoma can be occult and that an ectopic tumor rarely occurs.

Conventional T1-weighted MRI still is only able to detect approximately one third to one half of microadenomas.

Magnetic resonance imaging (MRI) may have a role in the diagnosis of Cushing disease. In one series, MRI with spoiled gradient recalled echo (SPGR) sequences detected adenomas in 15% of patients that were not detected by standard spin echo.[3] More sensitive imaging of the adenoma in Cushing disease confers several advantages, including confirmation of the diagnosis and location and avoidance of the risks of inferior petrosal sinus sampling; positive MRI findings help confirm the diagnosis of Cushing disease. Nevertheless, there is limited accuracy in the MRI's prediction of dural invasion.

Contributor Information and Disclosures

Alicia Diaz-Thomas, MD, MPH Assistant Professor of Pediatrics, University of Tennessee Health Science Center

Alicia Diaz-Thomas, MD, MPH is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, Tennessee Medical Association

Disclosure: Nothing to disclose.


Melanie Shim, MD 

Melanie Shim, MD is a member of the following medical societies: American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, American College of Endocrinology

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Thomas A Wilson, MD Professor of Clinical Pediatrics, Chief and Program Director, Division of Pediatric Endocrinology, Department of Pediatrics, The School of Medicine at Stony Brook University Medical Center

Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Pediatric Endocrine Society, Phi Beta Kappa

Disclosure: Nothing to disclose.


Robert J Ferry Jr, MD Le Bonheur Chair of Excellence in Endocrinology, Professor and Chief, Division of Pediatric Endocrinology and Metabolism, Department of Pediatrics, University of Tennessee Health Science Center

Robert J Ferry Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, American Medical Association, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, and Texas Pediatric Society

Disclosure: Eli Lilly & Co Grant/research funds Investigator; MacroGenics, Inc Grant/research funds Investigator; Ipsen, SA (formerly Tercica, Inc) Grant/research funds Investigator; NovoNordisk SA Grant/research funds Investigator; Diamyd Grant/research funds Investigator; Bristol-Myers-Squibb Grant/research funds Other; Amylin Other; Pfizer Grant/research funds Other; Takeda Grant/research funds Other

  1. Kasum M, Oreskovic S, Zec I, Jezek D, Tomic V, Gall V, et al. Macroprolactinemia: new insights in hyperprolactinemia. Biochem Med (Zagreb). 2012. 22(2):171-9. [Medline].

  2. Chaudhary V, Bano S. Imaging of pediatric pituitary endocrinopathies. Indian J Endocrinol Metab. 2012 Sep. 16(5):682-91. [Medline]. [Full Text].

  3. Lonser RR, Ksendzovsky A, Wind JJ, Vortmeyer AO, Oldfield EH. Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg. 2012 Feb. 116(2):272-9. [Medline].

  4. van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012 May. 97(5):1589-97. [Medline].

  5. Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 1997. 82:3196-202. [Medline].

  6. Avramides A, Karapiperis A, Triantafyllidou E, et al. TSH-secreting pituitary macroadenoma in an 11-year-old girl. Acta Paediatr. 1992. 81:1058-1060. [Medline].

  7. Benveniste RJ, King WA, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 2005. 102:1004-1012. [Medline].

  8. Booth GL, Redelmeier DA, Grosman H, et al. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. J Clin Endocrinol Metab. 1998 Jul. 83(7):2291-5. [Medline].

  9. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005. 8:3-6. [Medline].

  10. Colao A, Loche S, Cappabianca P. Pituitary adenomas in children and adolescents. Clinical presentation, diagnosis, and therapeutic strategies. The Endocrinologist. 2000. 10:314-27.

  11. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet. 1998 Oct 31. 352(9138):1455-61. [Medline].

  12. Cozzi R, Attanasio R, Barausse M, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?. Eur J Endocrinol. 1998 Nov. 139(5):516-21. [Medline].

  13. [Guideline] Cozzi R, Baldelli R, Colao A, Lasio G, Zini M, Attanasio R. AME Position Statement on clinical management of acromegaly. J Endocrinol Invest. 2009. 32(6 Suppl):2-25. [Medline].

  14. de Boer L, Hoogerbrugge CM, van Doorn J, et al. Plasma insulin-like growth factors (IGFs), IGF-Binding proteins (IGFBPs), acid-labile subunit (ALS) and IGFBP-3 proteolysis in individuals with clinical characteristics of Sotos syndrome. J Pediatr Endocrinol Metab. 2004. 17:615-627. [Medline].

  15. De Menis E, Visentin A, Billeci D, et al. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest. 2001. 24:92-97. [Medline].

  16. Dhillon KS, Cohan P, Kelly DF, et al. Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. J Clin Endocrinol Metab. 2004. 89:708-711. [Medline]. [Full Text].

  17. Duncan E, Wass JA. Investigation protocol: acromegaly and its investigation. Clin Endocrinol (Oxf). 1999 Mar. 50(3):285-93. [Medline].

  18. Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab. 1999 Dec. 84(12):4379-84. [Medline].

  19. Gillam MP, Fideleff H, Boquete HR, Molitch ME. Prolactin excess: treatment and toxicity. Pediatr Endocrinol Rev. 2004. 2:108-114. [Medline].

  20. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb. 85(2):526-9. [Medline].

  21. Gsponer J, De Tribolet N, Deruaz JP, et al. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore). 1999. 78:236-269. [Medline].

  22. Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990 Dec. 71(6):1427-33. [Medline].

  23. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab. 2000 Aug. 85(8):2958-61. [Medline]. [Full Text].

  24. Howell DL, Wasilewski K, Mazewski CM, et al. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. J Pediatr Hematol Oncol. 2005. 27:326-329. [Medline].

  25. Joshi SM, Hewitt RJ, Storr HL, et al. Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery. 2005. 57:281-285. [Medline].

  26. Kanter AS, Diallo AO, Jane JA Jr, et al. Single-center experience with pediatric Cushing's disease. J Neurosurg. 2005. 103:413-420. [Medline].

  27. Kiehna EN, Keil M, Lodish M, Stratakis C, Oldfield EH. Pseudotumor cerebri after surgical remission of Cushing's disease. J Clin Endocrinol Metab. 2010. 95:1528-32. [Medline]. [Full Text].

  28. Kunwar S, Wilson CB. Pediatric pituitary adenomas. J Clin Endocrinol Metab. 1999 Dec. 84(12):4385-9. [Medline].

  29. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab. 1999 Dec. 84(12):4317-23. [Medline].

  30. Lonser RR, Wind JJ, Nieman LK, Weil RJ, DeVroom HL, Oldfield EH. Outcome of surgical treatment of 200 children with Cushing's disease. J Clin Endocrinol Metab. 2013 Mar. 98(3):892-901. [Medline].

  31. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab. 1998 Aug. 83(8):2646-52. [Medline]. [Full Text].

  32. Mindermann T, Wilson CB. Pediatric pituitary adenomas. Neurosurgery. 1995 Feb. 36(2):259-68; discussion 269. [Medline].

  33. Newman CB. Medical therapy for acromegaly. Endocrinol Metab Clin North Am. 1999 Mar. 28(1):171-90. [Medline].

  34. Ng LL, Chasalow FI, Escobar O, Blethen SL. Growth hormone isoforms in a girl with gigantism. J Pediatr Endocrinol Metab. 1999. 126:99-106. [Medline].

  35. Oliveira Mda C, Abech DD, Barbosa-Coutinho LM, Ferreira NP. Macroprolactinoma at 6 years of age: diagnostic difficulties. [Portuguese]. Arq Neuropsiquiatr. 1992. 50:397-401. [Medline].

  36. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998 Aug. 83(8):2730-4. [Medline].

  37. Orth DN. Cushing's syndrome. N Engl J Med. 1995 Mar 23. 332(12):791-803. [Medline].

  38. Pandey P, Ojha BK, Mahapatra AK. Pediatric pituitary adenoma: a series of 42 patients. J Clin Neurosci. 2005. 12:124-127. [Medline].

  39. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005. 153:195-201. [Medline].

  40. Saito E, Correll CU, Gallelli K, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol. 2004. 14:350-358. [Medline].

  41. Sakazume S, Obata K, Takahashi E, et al. Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child. Eur J Pediatr. 2004. 163:472-474. [Medline].

  42. Smallridge RC. Thyrotropin-secreting pituitary tumors. Endocrinol Metab Clin North Am. 1987. 16:765-792. [Medline].

  43. Sotos JF. Overgrowth. Hormonal Causes. Clin Pediatr (Phila). 1996 Nov. 35(11):579-90. [Medline].

  44. Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol. 2005. 15:893-900. [Medline].

  45. [Guideline] Stewart PM, Petersenn S. Rationale for treatment and therapeutic options in Cushing's disease. Best Pract Res Clin Endocrinol Metab. 2009. 23 Suppl 1:S15-22. [Medline].

  46. Storr HL, Afshar F, Matson M, et al. Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol. 2005. 152:825-833. [Medline].

  47. Tamura T, Tanaka R, Korii K, Okazaki H. Pediatric pituitary adenoma. Endocr J. 2000. 47:S95-S99. [Medline].

  48. Thorner MO, Vance ML, Laws ER. The anterior pituitary. In: Wison JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa:. WB Saunders. 1998:249-340.

  49. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20. 342(16):1171-7. [Medline].

  50. van Haelst MM, Hoogeboom JJ, Baujat G, et al. Familial gigantism caused by an NSD1 mutation. Am J Med Genet A. 2005. 139:40-44. [Medline].

  51. van Haute FR, Taboada GF, Corrêa LL, Lima GA, Fontes R, Riello AP, et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008. 158:459-65. [Medline].

  52. Yang MH, Chuang H, Jung SM, et al. Pituitary apoplexy due to prolactinoma in a Taiwanese boy: patient report and review of the literature. J Pediatr Endocrinol Metab. 2003. 16:1301-1305. [Medline].

  53. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am. 1998 Mar. 27(1):109-26. [Medline].

Pituitary macroadenoma.
A 16-year-old boy with Cushing disease.
On the left is an unaffected patient aged 12 years. On the right is the same patient aged 13 years after developing Cushing disease.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.